Focus on headache as an adverse reaction to drugs

Journal of Headache and Pain

Volumn 10, Issue 4, 2009, Pages 235-239

  Ferrari, Anna ^a   Spaccapelo, Luca ^a   Gallesi, Daniela ^a   Sternieri, Emilio ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Adverse drug reaction; Classification; Headache; Migraine; Pharmacovigilance; Side effect

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMOXICILLIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIMIGRAINE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CALCITONIN GENE RELATED PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CLONIDINE; CYCLOPHOSPHAMIDE; DICLOFENAC; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERGOTAMINE; FAMOTIDINE; HISTAMINE; IBUPROFEN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; KETOROLAC; LEFLUNOMIDE; LEVAMISOLE; METHYLXANTHINE; METRONIDAZOLE; NAPROXEN; NITRIC OXIDE DONOR; PHOSPHODIESTERASE INHIBITOR; RANITIDINE; UNINDEXED DRUG;

CLUSTER HEADACHE; DISEASE CLASSIFICATION; DRUG EXPOSURE; DRUG INDUCED HEADACHE; HEALTH CARE COST; HUMAN; INCIDENCE; INTRACRANIAL PRESSURE; LONG TERM EXPOSURE; MIGRAINE; MORBIDITY; MORTALITY; PLACEBO EFFECT; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; QUALITY OF LIFE; REVIEW; TENSION HEADACHE; TREATMENT WITHDRAWAL; VASODILATATION;

ADVERSE DRUG REACTION REPORTING SYSTEMS; CLINICAL TRIALS AS TOPIC; CLUSTER HEADACHE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG TOXICITY; HEADACHE DISORDERS; HUMANS; MIGRAINE DISORDERS; TENSION-TYPE HEADACHE;

EID: 67650531870     PISSN: 11292369     EISSN: 11292377     Source Type: Journal    
DOI: 10.1007/s10194-009-0127-1     Document Type: Review

References (44)

1. Ferrari A (2006) Headache: One of the most common and troublesome adverse reactions to drugs. Curr Drug Saf 1:43-58
2. World Health Organization (1969) International drug monitoring: The role of the hospital. Tech Rep Ser 425:5-25
3. World Health Organization (1981) Cancer treatment: WHO recommendations for grading of acute and subacute toxicity. Cancer 47:207-214
4. Kessler DA (1993) MEDWatch: The new FDA medical products reporting program. Clin Pharm 12:529-532
5. Cohen JS (2002) Do standard doses of frequently prescribed drugs cause preventable adverse effects in women? J Am Med Womens Assoc 57:105-110
6. Park BK, Pirmohamed M, Kitteringham NR (1992) Idiosyncratic drug reactions: A mechanistic evaluation of risk factors. Br J Clin Pharmacol 34:377-395
7. Ju C, Uetrecht JP (2002) Mechanism of idiosyncratic drug reactions: reactive metabolite formation, protein binding and the regulation of the immune system. Curr Drug Metab 3:367-377
8. Nebeker JR, Barach P, Samore MH (2004) Clarifying adverse drug events: A clinician's guide to terminology, documentation, and reporting. Ann Intern Med 140:795-801
9. Hartford CG, Petchel KS, Mickail H et al (2006) Pharmacovigilance during the pre-approval phases: An evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelines. Drug Saf 29:657-673
10. Michels KB (1999) Problems assessing non-serious adverse drug reactions: antidepressant drug therapy and sexual dysfunction. Pharmacotherapy 19:424-429
11. Heeley E, Riley J, Layton D et al (2001) Prescription-event monitoring and reporting of adverse drug reactions. Lancet 358:1872-1873
12. Ioannidis JPA, Lau J (2002) Improving safety reporting from randomised trials. Drug Saf 25:77-84
13. Neidig JL, Koletar SL (2001) Safety reporting in clinical trials. J Am Med Assoc 285:2077-2078
14. Kaufman DW, Shapiro S (2002) Epidemiological assessment of drug-induced disease. Lancet 356:1339-1343
15. Hazell L, Shakir SA (2006) Under-reporting of adverse drug reactions: A systematic review. Drug Saf 29:385-396
16. Venulet J, ten Ham M (1996) Methods for monitoring and documenting adverse drug reactions. Int J Clin Pharmacol Ther 34:112-129
17. Headache Classification Subcommittee of the International Headache Society (2004) The International Classification of Headache Disorders, 2nd edn. Cephalalgia 24(Suppl 1):1-160
18. Rief W, Avorn J, Barsky AJ (2006) Medication-attributed adverse effects in placebo groups: Implications for assessment of adverse effects. Arch Intern Med 166:155-160
19. Hazard E, Munakata J, Bigal ME et al (2009) The burden of migraine in the United States: Current and emerging perspectives on disease management and economic analysis. Value Health 12:55-64
20. De Langen J, van Hunsel F, Passier A et al (2008) Adverse drug reaction reporting by patients in the Netherlands: Three years of experience. Drug Saf 31:515-524
21. Boada JN, Boada C, García-Sáiz M et al (2008) Net efficacy adjusted for risk (NEAR): A simplB procedure for measuring risk: benefit balance. PLoS ONE. doi: 10.1371/journal.pone.0003580
22. Veehof LJ, Stewart RE, Meyboom-de Jong B et al (1999) Adverse drug reactions and polypharmacy in the elderly in general practice. Eur J Clin Pharmacol 55:533-536
23. Jensen R, Stovner LJ (2008) Epidemiology and comorbidity of headache. Lancet Neurol 7:354-361
24. Zopf Y, Rabe C, Neubert A et al (2008) Women encounter ADRs more often than do men. Eur J Clin Pharmacol 64:999-1004
25. Ferrari A, Leone S, Vergoni AV et al (2007) Similarities and differences between chronic migraine and episodic migraine. Headache 47:65-72
26. Franceschi M, Scarcelli C, Niro V et al (2008) Prevalence, clinical features and avoidability of adverse drug reactions as cause of admission to a geriatric unit: A prospective study of 1756 patients. Drug Saf 31:545-556
27. Edwards IR, Aronson JK (2000) Adverse drug reactions: Definitions, diagnosis, and management. Lancet 356:1255-1259
28. White TJ, Arakelian A, Rho JP (1999) Counting the costs of drug-related adverse events. Pharmacoeconomics 15:445-458
29. Iversen HK, Olesen J (1994) Nitroglycerin-induced headache is not dependent on histamine release: Support for a direct nociceptive action of nitric oxide. Cephalalgia 14:437-442
30. Ross SD (2001) Drug-related adverse events: A readers' guide to assessing literature reviews and meta-analyses. Arch Intern Med 161:1041-1046
31. Steiger MJ, Farrah T, Rolles K et al (1994) Cyclosporin associated headache. J Neurol Neurosurg Psychiatry 57:1258-1259
32. Kruuse C, Lassen LH, Iversen HK et al (2006) Dipyridamole may induce migraine in patients with migraine without aura. Cephalalgia 26:925-933
33. Thomsen LL, Kruuse C, Iversen HK et al (1994) A nitric oxide donor (nitroglycerin) triggers genuine migraine attacks. Eur J Neurol 1:73-80
34. Evans RW, Kruuse C (2004) Phosphodiesterase-5 inhibitors and migraine. Headache 44:925-926
35. Khromov A, Segal M, Nissinoff J et al (2005) Migraines linked to interferon-beta treatment of multiple sclerosis. Am J Phys Med Rehabil 84:644-647
36. Khan RB (2002) Migraine-type headaches in children receiving chemotherapy and ondansetron. J Child Neurol 17:857-858
37. Ferrari U, Empl M, Kim KS et al (2005) Calcineurin inhibitor-induced headache: Clinical characteristics and possible mechanisms. Headache 45:211-214
38. Munera PA, Goldstein A (2001) Migraine and sertraline. J Am Acad Child Adolesc Psychiatry 40:1125-1126
39. Bank J (2001) Migraine with aura after administration of sublingual nitroglycerin tablets. Headache 41:84-87
40. Toth CC, Burak K, Becker W (2005) Recurrence of migraine with aura due to tacrolimus therapy in a liver transplant recipient successfully treated with sirolimus substitution. Headache 45:245-246
41. Larson EW (1993) Migraine with typical aura associated with fluoxetine therapy: Case report. J Clin Psychiatry 54:235-236
42. Dinn RB, Wall M (2006) Tadalafil associated with typical migraine aura without headache. Cephalalgia 26:1344-1346
43. Ekbom K (1968) Nitrolglycerin as a provocative agent in cluster headache. Arch Neurol 19:487-493
44. Evans RW (2006) Sildenafil can trigger cluster headaches. Headache 46:173-174